Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide

Journal of Immunology

Volumn 166, Issue 12, 2001, Pages 7151-7157

  Weijzen, S ^a   Meredith, S C ^a   Velders, M P ^a   Elmishad, A G ^a   Schreiber, H ^a   Kast, W M ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AD5 E1A; EPITOPE; HPV16 E7; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VACCINATION; VIRUS TITRATION; WART VIRUS;

EID: 0035877121     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.12.7151     Document Type: Article

References (29)

1. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide
2. Peptide-induced anti-viral protection by cytotoxic T cells
3. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
4. Peptide vaccination can lead to enhanced tumor growth through specific T cell tolerance induction
5. Enhanced tumor outgrowth after peptide vaccination: Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
6. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response
7. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
8. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
9. 254-262 in melanoma
10. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
11. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-Al
12. Vaccination with mutant ras peptides and induction of T cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation
13. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
14. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
15. Eradication of adenovirus El-induced tumors by E1A-specific cytotoxic T lymphocytes
16. 10-35 is parallel β-sheet with residues in exact register
17. Conformationally specific enhancement of receptor-mediated LDL binding and internalization by peptide models of a conserved anionic N-terminal domain of human apolipoprotein E
18. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity
19. T cell priming versus T cell tolerance induced by synthetic peptides
20. In vivo administration of major histocompatibility complex class I-specific peptides from influenza virus induced specific cytotoxic T cell hyporesponsiveness
21. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: Implications for dendritic cell-based vaccines
22. 27-35 peptide: Implications for peptide vaccines
23. Fas(CD95)/FasL interactions required for programmed cell death after T cell activation
24. Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo
25. TNF receptor 1 (TNFR1) and CD95 are not required for T cell deletion after virus infection but contribute to peptide-induced deletion under limited conditions
26. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
27. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences
28. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity